Shijiazhuang Pharmaceutical And Unigene Laboratories To Jointly Produce Osteoporosis Drug
This article was originally published in PharmAsia News
Shijiazhuang Pharmaceutical recently signed an agreement with U.S.-based Unigene Laboratories to co-invest $15 million in a firm to produce the anti-osteoporosis product Salmon Calcitonin. When in operation, the joint venture will produce 70 million Calcitonin injections and 4 million bottles of nasal spray, with an expected 708 million yuan in sales and $51.2 million in foreign exchange per year. In addition, an R&D platform for manufacturing biologics will be set up to develop and commercialize biotech drugs for an international market. (Click here for more)
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.